Humalog (Insulin Lispro)

Humalog is prescribed to manage blood glucose in diabetes mellitus when rapid insulin action is required. It is commonly used in the following situations:

• Mealtime (prandial) insulin coverage for type 1 diabetes.
• Mealtime (prandial) insulin coverage for type 2 diabetes.
• Supplemental insulin for patients on basal insulin regimens.
• Adjustment of insulin dose during illness or stress.
• Use in insulin pump therapy when rapid‑acting insulin is needed.

• Insulin lispro binds to insulin receptors on muscle and adipose cells, activating the receptor’s intrinsic tyrosine kinase activity. This triggers downstream signaling that promotes translocation of GLUT‑4 transporters to the cell membrane, increasing glucose uptake. Simultaneously, hepatic gluconeogenesis and glycogenolysis are suppressed, leading to a rapid decline in circulating glucose levels after subcutaneous administration.

Adverse reactions to Humalog can vary in frequency and severity.

Common

• Mild hypoglycemia (low blood sugar).
• Injection site redness, swelling, or itching.
• Lipodystrophy at the injection site.
• Transient weight gain.
• Headache.

Serious

• Severe hypoglycemia requiring assistance.
• Allergic reactions such as urticaria or angioedema.
• Anaphylactic shock (rare).
• Persistent hyperglycemia due to insulin resistance.
• Acute metabolic acidosis (euglycemic ketoacidosis).

When using Humalog, several safety considerations should be observed:

• Monitor blood glucose frequently, especially before meals and at bedtime.
• Adjust dose in renal or hepatic impairment to avoid hypoglycemia.
• Educate patients on recognizing and treating hypoglycemia promptly.
• Use caution during pregnancy; benefits must outweigh potential risks.
• Store the product according to label instructions to maintain potency.
• Do not use after the expiration date or if the solution is discolored.
• Consult a healthcare professional before switching insulin types.

Humalog may interact with other substances that affect glucose metabolism.

Avoid

• Concurrent use of other rapid‑acting insulins without proper dose adjustment.
• Administration of high‑dose beta‑blockers that mask hypoglycemia symptoms.

Use with caution

• Oral antidiabetic agents (e.g., sulfonylureas, meglitinides) that increase hypoglycemia risk.
• Alcohol consumption, which can potentiate insulin’s glucose‑lowering effect.
• Corticosteroids or thiazide diuretics that raise blood glucose levels.
• Beta‑agonists (e.g., albuterol) that may increase glucose levels.
• Thyroid hormones that can alter insulin requirements.